-50%

est. 2Y upside i

HealthcareSeries B

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Rank

#1925

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

NewLimit presents a moderate upside opportunity with higher risk.

Last updated: March 10, 2026

Bull (25%)+250%

Successful Phase 1/2 clinical trials for the liver rejuvenation program demonstrate strong safety and efficacy, leading to a major strategic partnership or acquisition by a large pharmaceutical company at a premium, pushing valuation to $5.67B (3.5x current) as the platform's broader potential is validated.

Base (30%)+50%

NewLimit makes steady preclinical and early clinical progress with its liver program, securing additional funding rounds. However, clinical data is mixed or slower than anticipated, and competition intensifies. The company maintains its valuation or sees moderate growth to $2.43B (1.5x current) based on continued platform development and preclinical validation.

Bear (45%)-60%

Clinical trials face significant delays or encounter safety/efficacy issues, or a competitor like Life Biosciences achieves a breakthrough first. The high capital intensity leads to a down round or difficulty raising further capital, resulting in a valuation decline to $0.648B (0.4x current), significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Funding Intensity

15%

Investors hold $215M in liquidation preferences ahead of common stock, representing 13.27% of the current $1.62B valuation.

Dilution Risk

high

As a clinical-stage biotech, NewLimit will require substantial additional funding rounds to advance through clinical trials, leading to significant future dilution for existing equity holders.

Secondary Liquidity

limited

NewLimit stock is a private security, with trading available only to accredited investors through secondary marketplaces like Nasdaq Private Market, indicating limited liquidity.

Other — 11 roles

View all 11 open roles at NewLimit →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on NewLimit's data — designed to show you've done your homework.

  • 1

    “Given that Life Biosciences has already received FDA clearance for an IND for its partial epigenetic reprogramming therapy, how does NewLimit plan to differentiate its clinical development strategy and accelerate its path to human trials?”

  • 2

    “With the goal of expanding from specific age-related diseases to broader patient populations, what are the key preclinical or early clinical data points that the team believes will be most compelling to regulators and future partners?”

  • 3

    “Considering the high capital intensity of biotech development and the current $1.62B valuation, what is the company's anticipated fundraising strategy over the next 2-3 years, and how does it plan to manage potential dilution for employees?”

Community

Valuation Sentiment

Our model estimates -50% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.